Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LIFT-57
London, England, United Kingdomcsufama.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Preclinical data show that Immunomodulatory Alpha Neutrophils (IMANs) can kill cancer cells directly and modulate the tumor microenvironment to overcome treatment resistance. The company is preparing for its first clinical trials in solid tumors and has presented promising preclinical results at major scientific meetings.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyAllogeneic neutrophil-based cell therapy (Immunomodulatory Alpha Neutrophils, IMANs)Engineered CAR IMAN cell therapies
- Industry
- Biotech
02
Partnerships
Gift of Life BiologicsUniversity of Galway
Beyond the preview
Go deeper on LIFT-57.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIFT-57.